Analysis of three epoetin alpha products by LC and LC-MS indicates differences in glycosylation critical quality attributes, including sialic acid content by Thomson, Rebecca I. et al.
Analysis of Three Epoetin Alpha Products by LC and LC-MS Indicates
Diﬀerences in Glycosylation Critical Quality Attributes, Including
Sialic Acid Content
Rebecca I. Thomson,† Richard A. Gardner,‡ Katja Strohfeldt,† Daryl L. Fernandes,‡ Graham P. Staﬀord,§
Daniel I. R. Spencer,*,‡ and Helen M. I. Osborn*,†
†Reading School of Pharmacy, University of Reading, Reading, Berkshire RG6 6AP, United Kingdom
‡Ludger, Ltd., Culham Science Centre, Abingdon, Oxfordshire OX14 3EB, United Kingdom
§Integrated BioSciences, School of Clinical Dentistry, University of Sheﬃeld, Sheﬃeld, S10 2TA, United Kingdom
*S Supporting Information
ABSTRACT: Erythropoietin (EPO) is one of the main
therapeutics used to treat anemic patients, greatly improving
their quality of life. In this study, biosimilars Binocrit and a
development product, called here CIGB-EPO, were compared
to the originator product, Eprex. All three are epoetin alpha
products, reputed to have similar glycosylation proﬁles. The
quality, safety, and eﬃcacy of this biotherapeutic depend on
the following glycosylation critical quality attributes (GCQAs):
sialylation, N-glycolyl-neuraminic acid (Neu5Gc) content,
branching, N-acetyl-lactosamine (LacNAc) extensions, and
O-acetylation pattern. Reverse-phase ultra-high-pressure liquid
chromatography (RP-UHPLC) analysis of acid-released, 1,2-diamino-4,5-methylenedioxybenzene (DMB) labeled sialic acid
derivatives and hydrophilic interaction liquid chromatography (HILIC) in combination with mass spectrometry (HILIC-
UHPLC-MS) of procainamide (PROC) labeled N-glycans were the analytical tools used. An automated method for enzymatic
release and PROC labeling was applied for the ﬁrst time to the erythropoiesis stimulating agent (ESA) products, which facilitated
novel, in-depth characterization, and allowed identiﬁcation of precise structural features including the location of O-acetyl groups
on sialic acid (SA) moieties. Samples were digested by a sialate-O-acetylesterase (NanS) to conﬁrm the presence of O-acetyl
groups. It was found that Eprex contained the greatest relative abundance of O-acetylated derivatives, Binocrit expressed the least
Neu5Gc, and CIGB-EPO showed the greatest variety of high-mannose-phosphate structures. The sialylation and LacNAc
extension patterns of the three ESAs were similar, with a maximum of four N-acetyl-neuraminic acid (Neu5Ac) moieties detected
per glycan. Such diﬀerences in SA derivatization, particularly O-acetylation, could have consequences for the quality and safety of
a biotherapeutic, as well as its eﬃcacy.
Erythropoietin (EPO) is a mammalian glycoproteinhormone, mainly produced in the kidney, that regulates
the level of red blood cells in circulation.1 It is recognized as a
medicinal product for the treatment of anemia due to renal
failure or chemotherapy.2 Unfortunately, EPO is often also
exploited as a doping strategy by athletes.3 Detection of the
illegal use of synthetic EPO analogues, known as erythropoiesis
stimulating agents (ESAs), is complicated by the ongoing
development of biotherapeutics with longer bloodstream
lifetimes.4
The ﬁrst commercially available ESA was an epoetin alpha
brand-named Eprex.2 Expiration of the epoetin alpha patent in
Europe in 2004 allowed “biosimilar” ESAs to enter the market.
When developing a biosimilar it must be proven that the
proposed biotherapeutic yields neither a better nor worse result
compared to the originator product.5 Moreover, structural
information must be presented to the relevant regulating body.
For EPO, which contains highly sialylated glycans, product
glycosylation may diﬀer between biosimilars, and this should
therefore be monitored by deﬁning and measuring glycoprotein
critical quality attributes (GCQAs).
Particularly important components of the glycan chain are
sialic acids (SAs). Of particular note, an ESA containing up to
eight extra SA residues shows a 3-fold increase in serum half-
life.6 Moreover, the main diﬀerence between human serum
EPO and recombinant human EPO is a lack of tetra-sialylated
structures in the former.7
N-Linked rather than O-linked glycans inﬂuence the eﬃcacy
of EPO, with the SA residues on the N-glycans being the key
components necessary for in vivo activity.8,9 Within the N-
glycan characteristics of EPO, the length of lactosamine
(LacNAc) repeats and amount of structural branching can
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also aﬀect the lifetime of a biosimilar.10 O-Acetylation of SAs,
which has been shown to increase hydrophobicity of this sugar
and inhibit sialidase action,11 has been hypothesized as another
mechanism to retain glycoproteins in the bloodstream.12 Aside
from N-acetylneuraminic acid (Neu5Ac) content, the presence
of N-glycolylneuraminic acid (Neu5Gc) must be monitored, as
humans express antibodies directed against it that cause rapid
clearance of Neu5Gc-containing biotherapeutics from the
bloodstream.13
As the originator product, Eprex is taken as the standard ESA
against which all other treatments are compared.14 The ﬁrst
approved biosimilar to Eprex, also an epoetin alpha, was brand-
named “Binocrit”. CIGB-EPO is an epoetin alpha still under
development.15 Eprex and Binocrit have both been shown to
consist of six isoforms, but with diﬀering abundances.16
As all three ESAs fall under the category of epoetin alpha,
denoting Chinese hamster ovary (CHO) cell line manufac-
ture,17 their glycosylation proﬁles are expected to be very
similar although not identical, as the biochemical processes
depend on a range of conditions that can vary between
manufacturers and even between batches.5 The monitoring of
such variations in glycan structure is essential as it could
potentially account for diﬀerences in immunogenicity, half-life
of the ESAs, and eﬃcacy of the products.2,18
In view of the impact of SA proﬁle on the lifetime of ESAs in
the bloodstream and its further possible role in adverse eﬀects,
the present investigation centered on this aspect, particularly
the lesser examined O-acetylation pattern. The branched nature
of N-glycans, coupled with the diﬀerent ring sizes and
anomericity of their constituent monosaccharides, make them
notoriously diﬃcult to analyze.19 Thus, the approach taken was
to use liquid chromatography coupled with mass spectrometry
(LC-MS) employing two diﬀerent ﬂuorescent tags: DMB for
identiﬁcation of diﬀerent O-acetylated SA derivatives and
PROC labeling of released N-glycans. O-Acetylation content
was conﬁrmed using an O-acetylesterase. A Hamilton Microlab
STARlet liquid-handling robot was used with a view to
automating sample preparation and facilitating faster analysis
of glycans labeled with an LC-MS compatible ﬂuorophore tag.
■ MATERIALS AND METHODS
Erythropoiesis Stimulating Agents (ESAs). Licensed
EPO products Eprex (Janssen-Cilag) and Binocrit (Sandoz)
were purchased from a certiﬁed pharmacy. A development ESA,
named CIGB-EPO, was a gift from Antonio Vallin, Center for
Molecular Immunology, Cuba. The samples were buﬀer
exchanged into water using Vivaspin 6 devices (MWCO
10,000) (Sartorius). To aid maximum possible recovery of the
sample, the Vivaspins were rinsed twice with water and the
washes added to the previously exchanged material. Each ESA
was buﬀer-exchanged in the same way to enable direct
comparison of results. The samples were then stored below 0
°C. Method outlines are given in the following subsections and
more detail can be found in the Supporting Information.
Sialic Acid (SA) Analysis. Release and ﬂuorescence
labeling of the SAs was carried out using a DMB sialic acid
release and labeling kit (Ludger) as previously described in the
literature.20 The released and labeled samples, standard, and
reference thus obtained were diluted by 1 in 10 and analyzed by
RP-HPLC on a LudgerSep-uR2 C18 100 × 2.1 mm, i.d. 1.7 μm
column, elution gradient methanol/acetonitrile/water. An
Ultimate 3000 UHPLC (Thermo) equipped with a ﬂuores-
cence detector (FD) was used (excitation wavelength 373 nm,
emission wavelength 448 nm) and data were analyzed using the
Chromeleon 7.2 software. Each ESA was run three times, that is
three separately released and labeled samples.
N-Glycan Analysis. Denaturation, Release, and Labeling.
A Hamilton Microlab STARlet liquid-handling robot was used
for sample preparation of the N-glycans in a similar manner to
that previously published.21,22 A procainamide labeling kit
(Ludger) containing 2-picoline borane was used, as described
by Kozak et al., again employing the Hamilton Microlab
STARlet liquid-handling robot.23 Samples were analyzed by
HILIC-LC on an Ultimate 3000 UHPLC using a BEH-Glycan
1.7 μm, 2.1 × 150 mm column (Waters) at 40 °C with a
ﬂuorescence detector (λex = 310 nm, λem = 370 nm), controlled
by Bruker HyStar 3.2. Buﬀer A was 50 mM ammonium formate
made from LudgerSep N Buﬀer stock solution, pH4.4 [LS-N-
BUFFX40]; buﬀer B was acetonitrile (acetonitrile 190 far UV/
gradient quality; Romil #H049). Samples were injected in 24%
aqueous/76% acetonitrile; injection volume 25 μL. Chrome-
leon data software version 7.2 with a cubic spline ﬁt was used to
allocate glucose unit (GU) values to peaks. PROC labeled
glucose homopolymer was used as a system suitability standard
as well as an external calibration standard for GU allocation for
the system.24 Each ESA was run in quadruplicate.
Mass Spectrometry (MS). A Bruker amaZon Speed ETD
electrospray mass spectrometer was coupled directly after the
UHPLC FD without splitting. The instrument scanned samples
in maximum resolution mode, positive ion setting, MS scan +
three MS/MS scans, nebulizer pressure 14.5 psi, nitrogen ﬂow
10 L/min, capillary voltage 4500 V. MS/MS was performed on
three ions in each scan sweep with a mixing time of 40 ms.
Mass spectrometry data were analyzed using the Bruker
Compass DataAnalysis 4.1 software in combination with
Bruker Proteinscape 4.0 for assisting peak assignments to a
Ludger EPO glycan database. Structures were identiﬁed by
comparing LC, MS, and MS/MS data.
O-Acetylesterase Digest. Sets of PROC-labeled N-glycans
released from each ESA were subjected to enzyme digest by
NanS (LZ-ACASE-KIT, Ludger), speciﬁc for the removal of 7-,
8-, and 9-O-acetyl groups, as described in the literature.25,26
Brieﬂy, 1 μL of enzyme (0.7 mg/mL) was added to each
sample and buﬀer (50 mM sodium acetate buﬀer, pH 5.5) was
added to give a total volume of 10 μL before incubation at 37°
for 16 h. The enzyme was removed using a protein-binding
plate and the resulting samples analyzed by HILIC-UHPLC.
Each digest was only carried out once.
■ RESULTS
1,2-Diamino-4,5-methylenedioxybenzene (DMB)
Analysis. DMB-labeling of acid released SAs is an established
method allowing comparison between samples and concur-
rently run references and standards. The sialic acid reference
panel (SRP), derived from a mild digest of bovine submaxillary
mucin, is well-known and characterized in the literature.27 SRP
and GPEP (a biantennary disialylated N-glycan linked to
peptide KVANKT) acted as positive controls to conﬁrm
successful labeling. Comparison of GPEP with the SRP showed
that it contained just Neu5Ac as expected. Excluding the free
dye peak at retention time 5.10 min, the relative abundance of
each SA structure present in the ESA samples was calculated
(Figure 1). The results showed good repeatability (Figure S1).
Where the average relative area of the peak is >0.5%, the
relative standard deviation (RSD) value should be <10%, but
where the average relative area of the peak is <0.5%, the RSD
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value should be <30%, as indicated in green (Figures S2−S4
and Tables S1−S3). This was the case for most of the peaks in
the current study. Absolute abundances have not been
calculated because the quantity of material that was buﬀer
exchanged can only be estimated.
Although the O-acetylation pattern of ESA products is clearly
similar in terms of the types of SA structure present, there are
diﬀerences in the relative abundances of many species.
Strikingly, Neu5Gc is expressed to a similar degree in both
Eprex and CIGB-EPO, whereas Binocrit shows almost half the
relative quantity. On the other hand, similarity between
Binocrit and CIGB-EPO can be seen in the relative abundance
of N-8-O-acetyl-acetylneuraminic acid (Neu5,8Ac2) and N-9-O-
acetyl-acetylneuraminic acid (Neu5,9Ac2), but the relative
abundance of these two species in Eprex is double. Di-O-
acetylation in the form of Neu5,7,9Ac3 is present in all three
ESA products, but in a broad range of 0.1−2.6%.
Procainamide (PROC) Analysis. UHPLC traces for the
PNGase F released, PROC-labeled N-glycans of the ESAs were
obtained (Figure 2). Samples were run in quadruplicate with
good repeatability evidenced by low RSD values (Figures S11−
S13 and Tables S4−S6). Integration of peaks was achieved
using Chromeleon software on an Ultimate 3000 UHPLC.
Glycan peak (GP) numbers were assigned by taking into
account GU values alongside carbohydrate content of peaks.
The structures contained in each LC peak were identiﬁed by
examining the corresponding MS and MS/MS data (Tables
S7−S9) and the traces have been labeled accordingly. The
“Oxford notation” nomenclature has been used for the linear
notation but without strict adherence to linkage type.28
In general, the more highly O-acetylated a structure, the
sooner it elutes because of increased hydrophobicity, and the
more branching or chains that the glycans form, the longer the
retention time. Some structures, such as FA2G2S2(Ac)2,
appear in all ESAs, albeit at slightly diﬀerent GU values (GP
3, 6, and 7 of Figure 2). Shifts in GU between structures of
apparently the same constituents are usually due to the
presence of diﬀerent isomers. The majority of structures are
believed to be core fucosylated, as previous studies have found
this to be the most likely position of the fucose residue.29
Primarily, glycan structures were assigned according to the
MS data. The MS/MS data obtained was used to determine the
position of O-acetyl groups on SA residues. Of particular
relevance to this study were the fragments: m/z 657.16
(HexHexNAcNeuAc), m/z 699.17 (HexHexNAcNeuAc-
(+1Ac)), and m/z 741.18 (HexHexNAcNeuAc(+2Ac)). If
found, these fragments provide evidence as to where the O-
acetyl groups were located. For example, the Eprex MS/MS of
peak m/z 891.79 fragmented into m/z 657 and m/z 741
alongside an absence of m/z 699, indicating that the two O-
acetyl groups were located on the same SA (Figure 3 and
Tables S10 and S11). Conversely, m/z 877.61 contained
fragments m/z 657 and m/z 699 without m/z 741, showing
that a SA was singly O-acetylated. Also of interest in this study
was m/z 672.23, corresponding to Neu5Gc (Figure S14).
Limitations of the MS method used for peak identiﬁcation
include the inability to distinguish between greater branching of
the core structure of the glycan as opposed to extended
LacNAc repeats, such as between FA4G4S3 and FA3G3S3-
(LacNAc)1 (GP 33 of Figure 2). Strengths of the method
include the high ﬂuorescence intensity of derivatives and good
sensitivity. Use of the milder ESI as opposed to matrix assisted
laser desorption/ionization (MALDI) ensured that there was
neither loss of SA moieties nor migration of O-acetyl
groups.12,19
Enzyme Digest. PROC-labeled ESAs were analyzed by
UHPLC before and after digestion with an O-acetylesterase
that removed all 7-, 8-, and 9-O-acetyl moieties of SA and the
resulting traces were compared (Figure 4). As expected, peaks
from the original sample that contained such O-acetylated SA
derivatives disappeared after incubation with the enzyme. This
was particularly pronounced for Eprex, which shows a markedly
altered proﬁle after digest, thus conﬁrming the highly O-
acetylated nature of its N-linked glycans.
■ DISCUSSION
When developing a glycoprotein as a biotherapeutic, quality,
safety, and eﬃcacy are the most important criteria to
consider.18 For an ESA, the GCQAs aﬀecting these criteria
are sialylation, level of Neu5Gc, core glycan structures, LacNAc
extensions, and arguably, acetylation pattern.30
Sialylation is readily present in all of the ESAs analyzed, with
a maximum of four SA moieties present on some glycan
structures, similar to literature reports.7,30 A greater number of
SA moieties is known to extend the half-life of an
erythropoietin, thus improving its eﬃcacy.6 A greater degree
of O-acetylation of SA is also thought to improve therapeutic
half-life as its presence has been shown to slow the action of
sialidases.11,12 In the literature, although still debated, there is
evidence to suggest that migration from the 7- to the 9-position
of the SA structure is not purely because of pH changes but is
accelerated by a so-called “migrase”.31 Once at the 9-position,
the O-acetyl group’s removal can be eﬀected by the sialidase,
leaving the underlying galactose residue exposed to hepatocyte
receptors.32 Arguably, therefore, not only the extent but also
the position of an O-acetyl group could aﬀect the half-life of a
biotherapeutic.
Although DMB has previously been used to label SAs
released from ESAs, the authors of that study did not take
advantage of the DMB method in order to calculate the relative
abundances of all derivatives detected, nor was the process
automated.30 In the present study, DMB analysis shows the
presence of mono- and di-O-acetylation of Neu5Ac in all three
ESA products, but in varying relative abundances. Eprex
comprises a relative abundance of 15.1% of O-acetylated SA,
compared to 8.6% for Binocrit and 6.9% for CIGB-EPO
(Figure 1). This observation is supported by the PROC labeled
Figure 1. RP-HPLC traces of standard and ESA DMB derivatives.
Relative percentage area is given above each peak. Mono- and di-O-
acetylated SAs contained in samples can be identiﬁed by comparison
to the SRP. Assignments based on Klein et al.27
Analytical Chemistry Article
DOI: 10.1021/acs.analchem.7b00353
Anal. Chem. XXXX, XXX, XXX−XXX
C
N-glycan analysis (Figure 2), although it must be borne in mind
that SAs from both O- and N-glycans were released for DMB
labeling. The presence of di-O-acetylated Neu5Ac in Eprex is
spread across a range of diﬀerent N-glycan structures. Despite
Figure 2. Fluorescence chromatogram for each PROC-labeled ESA. The brackets show where diﬀerent classes of glycan are most commonly found:
high mannose (green), O-acetylated (pink) and LacNAc (blue). See Figures S5−S7 for more detailed versions of these images together with Figures
S9−11 that show the corresponding base peak chromatograms (BPCs) and MS/MS chromatograms.
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this, a large proportion of the O-acetylation in Eprex stems
from the high relative abundance of Neu5,7,9Ac3 (2.6%)
(Figure 1). Furthermore, this high level of O-acetylation in
Eprex is evidenced by the dramatic collapse of the complex
HPLC chromatogram to a much simpler one after incubation
with NanS (Figure 4). On the other hand, arguably CIGB-EPO
demonstrates the greatest extent of O-acetylation, as it is the
only one shown by PROC labeling to contain up to six O-acetyl
groups on one glycan: FA4G4S4Ac6 (GP 11, 12, and 17 of
Figure 2).
Previous work has illustrated the potential immunogenicity
of Neu5Gc and the necessity to keep levels of this SA to a
minimum in biotherapeutics.13 DMB analysis in the current
study indicates that CIGB-EPO contains the least Neu5Gc
(Figure 1), which is supported by the PROC analysis (Figure
S14).
The current study also conﬁrms the presence of a high-
mannose-6-phosphate structure in Binocrit, previously detected
by Brockmeyer et al.33 There is limited evidence of high
mannose structures in Eprex, whereas higher percentage areas
of such structures are apparent in CIGB-EPO. Fucosylation of
the majority of the structures in the present study has been
found.
Eprex has been subjected to examination in a previous report
by Shakrokh et al.30 However, the authors used a slightly
diﬀerent method in the form of weak anion exchange (WAX)
HPLC on a 5 μm column, rather than HILIC-LC analysis of
PROC labeled samples. This could account for the greater level
of detail found in the current study from the intact glycans and
MS fragments, particularly in terms of where the O-acetyl
groups were located on the glycan, thus allowing the detection
of additional structures such as FA4G4S4AcLacNAc (GP 35 of
Figure 2). In addition, these earlier WAX HPLC columns
yielded poorer spectral resolution. Other structural divergences,
including the lack of FA2G2 and FA2G2S4LacNAc in the
current analysis, could be due to batch diﬀerences. That said,
initial licensing of a biosimilar is based on analysis across several
batches and later batch−batch variation is strictly regulated by
consistent manufacturing processes and purity and activity
proﬁling.2
Studies have shown that the N-glycans as opposed to the O-
glycans are responsible for the biological activity of EPO.8
Moreover, although a number of techniques for O-glycan
release are outlined in the literature, compatibility with
ﬂuorescence labeling is currently only guaranteed using
hydrazinolysis.34 Thus, not only could this remove O-acetyl
groups from SAs, but the “re-N-acetylation” step, for which an
Figure 3. MS/MS spectra for m/z 891.79 and m/z 877.61, showing probable structures. Symbols are used according to the Consortium for
Functional Glycomics. For further details refer to Tables S10 and S11.
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excess of acetic anhydride is used, could acetylate hydroxyls that
were underivatised in the original material.35 For these reasons,
analysis of the N-glycans was prioritised here.
It has been postulated that the hydrodynamic size of EPO
inﬂuences its in vivo bioactivity.36 This not only depends on the
SA content but also the LacNAc composition that forms either
branched or repeat units. To the authors’ knowledge, to date
there is no literature outlining the eﬀect on bioavailability of the
presence of branching compared to extensions of LacNAc.
However, it is widely accepted that branching leads to
improved in vivo bioactivity, but longer chains result in quicker
clearance.10,37 Glycoproteins containing LacNAc repeats with
terminal sialylation or fucosylation are ligands for selectins,
which could therefore play a role in EPO behavior.38 Although
in this study it cannot be deﬁnitively stated that, for example,
structure FA4G4S3LacNAc is not in fact FA3G3S3(LacNac)2
(GP 38−40 of Figure 2), it is still worth noting that a similar
pattern of LacNAc repeats/branching is seen between the ESA
products. Bisecting glycans were not expected using this
expression system.39
Particular aspects of the N-glycans of ESAs can be ﬁne-tuned
by the alteration of cell line production conditions, for example,
the SA content: CHO cells can be engineered to express either
more sialidase or more sialyltransferase; thus, the glycans are
sialylated to a lesser or greater extent, respectively.40 Changes
to cell growth conditions in the bioreactor could also change
glycosylation features. Studies such as the present one will help
to build a picture of the most desirable GCQAs that an ESA
product should have, thereby increasing the eﬃcacy while
maintaining quality and safety.
Aside from O-acetylesterase, complementary exoglycosidase
digestions could yield more detail and conﬁrm assignments
made by LC-MS analysis. Fucosidases could be used to check
for outer-arm fucose moieties and galactosidases and sialidases
of diﬀerent speciﬁcity would help to determine the linkage
patterns between substituents.
In the present study, solely alpha epoetins were analyzed, but
in a further study, it could be beneﬁcial to see whether other
ESA biosimilars for example NeoRecormon (beta), Eporatio
(theta), or Retacrit (zeta), oﬀer similar O-acetylation patterns.
Indeed, such an analysis could be extended to other
biotherapeutics; one possibility is follicle stimulating hormone
(FSH) or the recently licensed monoclonal antibody biosimilar
Inﬂiximab. Some diﬀerences between the Eprex of the present
study and the Eprex of Shahrokh et al. were noted, which could
be due to batch diﬀerences and therefore a study across
diﬀerent batches of the same ESA could give further insight.
■ CONCLUSIONS
Three ESA products, namely, Eprex, Binocrit, and CIGB-EPO,
have been subjected to three forms of analysis to compare
GCQAs. First, through RP-HPLC analysis of acid-released,
DMB labeled SA derivatives, it has been demonstrated that
Eprex contains the greatest relative abundance of O-acetylated
derivatives, mainly, because of high levels of Neu5,9Ac2 and
Neu5,7,9Ac3. Binocrit has been found to contain the least
Neu5Gc, a SA known to evoke an immune response in humans.
Second, PROC labeled N-glycans run on HILIC-UHPLC-MS
also showed high levels of O-acetylation, with up to six O-acetyl
groups on one structure seen in CIGB-EPO. Finally, peak
assignment was conﬁrmed by O-acetylesterase digestion. This
O-acetylation, alongside fucosylation and LacNAc repeats,
could inﬂuence lifetime in the bloodstream (as hepatic removal
could be regulated through the presence of O-acetyl groups on
the SA), as well as aﬀect the quality and safety of the ESA
products.
Outlined in this Article for the ﬁrst time is a detailed analysis
of PROC-labeled glycans from ESAs, achieved with automated
sample preparation. Automated sample preparation was also
used for the ﬁrst time for DMB analysis and the relative
abundance of each SA derivative was calculated. The employed
combination of methods made the recognition of distinct
glycan features possible, such as a SA with one or two O-acetyl
groups in the presence of a SA with no extra acetylation.
In the case of fully licensed Eprex and Binocrit, the above
characteristics may only now be being observed but should not
be a cause for concern unless deﬁnitively linked to adverse
eﬀects. Binocrit has previously been shown to contain high-
mannose-phosphate structures; therefore, their presence in
CIGB-EPO may not be a disadvantage but must be coupled
with further analysis and clinical trial to conclusively determine
its eﬀect. Taking into account the diﬀerences between
ostensibly similar products and the relative ease of analysis
aﬀorded by the methods used in the current study, it is
recommended that all ESAs be analyzed to this level of detail in
the future.
Figure 4. Fluorescence chromatograms of Eprex, Binocrit, and CIGB-
EPO before (blue, green and red, respectively) and after (black)
incubation with an O-acetylesterase. The CIGB-EPO digest has
previously been published by the author in collaboration with
Phansopa et al.25 Part of ﬁgure adapted with permission from ref
25. Copyright 2015 The Biochemical Society.
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